Editas Medicine, Inc. (EDIT): Price and Financial Metrics

Editas Medicine, Inc. (EDIT): $7.72

0.41 (-5.04%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add EDIT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#138 of 360

in industry

EDIT Price/Volume Stats

Current price $7.72 52-week high $11.91
Prev. close $8.13 52-week low $6.08
Day low $7.70 Volume 2,658,300
Day high $8.15 Avg. volume 1,880,087
50-day MA $8.35 Dividend yield N/A
200-day MA $8.66 Market Cap 631.60M

EDIT Stock Price Chart Interactive Chart >

EDIT POWR Grades

  • Growth is the dimension where EDIT ranks best; there it ranks ahead of 73.34% of US stocks.
  • The strongest trend for EDIT is in Growth, which has been heading up over the past 26 weeks.
  • EDIT ranks lowest in Stability; there it ranks in the 3rd percentile.

EDIT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for EDIT is 0.07 -- better than just 12.24% of US stocks.
  • With a price/sales ratio of 31.43, EDITAS MEDICINE INC has a higher such ratio than 95.59% of stocks in our set.
  • With a year-over-year growth in debt of 62.48%, EDITAS MEDICINE INC's debt growth rate surpasses 88.46% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to EDITAS MEDICINE INC, a group of peers worth examining would be FUSN, GSIT, HYLN, SLDP, and ITOS.
  • EDIT's SEC filings can be seen here. And to visit EDITAS MEDICINE INC's official web site, go to www.editasmedicine.com.

EDIT Valuation Summary

  • In comparison to the median Healthcare stock, EDIT's price/sales ratio is 1427.27% higher, now standing at 33.6.
  • EDIT's price/sales ratio has moved down 365.2 over the prior 96 months.

Below are key valuation metrics over time for EDIT.

Stock Date P/S P/B P/E EV/EBIT
EDIT 2023-12-29 33.6 2.3 -4.2 -3.7
EDIT 2023-12-28 34.3 2.3 -4.3 -3.8
EDIT 2023-12-27 34.4 2.4 -4.3 -3.8
EDIT 2023-12-26 35.4 2.4 -4.5 -3.9
EDIT 2023-12-22 35.9 2.5 -4.5 -4.0
EDIT 2023-12-21 34.3 2.3 -4.3 -3.8

EDIT Growth Metrics

    The 2 year revenue growth rate now stands at 6.74%.
  • Its year over year revenue growth rate is now at -71.79%.
  • Its year over year cash and equivalents growth rate is now at -40.58%.
EDIT's revenue has moved up $5,113,000 over the prior 33 months.

The table below shows EDIT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 25.644 -169.658 -201.13
2022-06-30 31.799 -162.439 -184.486
2022-03-31 25.816 -163.551 -186.289
2021-12-31 25.544 -163.803 -192.502
2021-09-30 24.494 -169.321 -213.565
2021-06-30 81.138 -183.337 -166.664

EDIT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EDIT has a Quality Grade of D, ranking ahead of 12.21% of graded US stocks.
  • EDIT's asset turnover comes in at 0.12 -- ranking 248th of 682 Pharmaceutical Products stocks.
  • SMMT, SAGE, and VSTM are the stocks whose asset turnover ratios are most correlated with EDIT.

The table below shows EDIT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.120 1 -0.458
2021-03-31 0.140 1 -0.450
2020-12-31 0.158 1 -0.468
2020-09-30 0.164 1 -0.447
2020-06-30 0.065 1 -0.704
2020-03-31 0.057 1 -0.806

EDIT Price Target

For more insight on analysts targets of EDIT, see our EDIT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $50.75 Average Broker Recommendation 1.79 (Moderate Buy)

Editas Medicine, Inc. (EDIT) Company Bio


Editas Medicine Inc. operates as a genome editing company. It focuses on translating its genome editing technology into a class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a range of diseases at the genetic level. Editas Medicine Inc. was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. The company was founded in 2013 and is based in Cambridge, Massachusetts.


EDIT Latest News Stream


Event/Time News Detail
Loading, please wait...

EDIT Latest Social Stream


Loading social stream, please wait...

View Full EDIT Social Stream

Latest EDIT News From Around the Web

Below are the latest news stories about EDITAS MEDICINE INC that investors may wish to consider to help them evaluate EDIT as an investment opportunity.

Editas Just Caught a Break Thanks to Vertex Pharmaceuticals

Editas isn't out of the woods yet, but it's better off than before.

Yahoo | December 23, 2023

Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 23%

Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders will have a reason to smile today, with the analysts making...

Yahoo | December 15, 2023

The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics

bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog.

Yahoo | December 14, 2023

Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News

bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.

Yahoo | December 14, 2023

Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%

Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy.

Yahoo | December 14, 2023

Read More 'EDIT' Stories Here

EDIT Price Returns

1-mo -5.28%
3-mo -24.39%
6-mo -3.50%
1-year -5.85%
3-year -82.84%
5-year -68.80%
YTD -23.79%
2023 14.21%
2022 -66.59%
2021 -62.13%
2020 136.78%
2019 30.15%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!